[144] Nektar Therapeutics SEC Filing

Rhea-AI Filing Summary

Nektar Therapeutics (NKTR) filing reports a proposed sale of 5,166 common shares through Fidelity Brokerage Services with an aggregate market value of $174,119.16, to be sold approximately on 09/04/2025 on NASDAQ. The filing details that these shares were acquired via restricted stock vesting between 11/15/2017 and 05/15/2019, totaling specified lots (190; 1,346; 1,073; 1,072; 1,011; 474). It also discloses recent sales by the same person: 1,573 shares on 08/19/2025 for $41,826.23 and 1,500 shares on 09/02/2025 for $45,243.50. The signer represents no undisclosed material adverse information.

Positive

• Full disclosure of acquisition history by lot with dates and nature of acquisition (restricted stock vesting).
• Broker and planned sale details provided, including exchange (NASDAQ) and aggregate market value ($174,119.16).

Negative

• Insider has recently sold shares (1,573 on 08/19/2025 and 1,500 on 09/02/2025), which may be relevant to investors evaluating insider activity.

Insights

Securities Analyst

TL;DR Proposed sale is modest in size and follows recent smaller dispositions by the same holder.

The filing notifies a planned sale of 5,166 common shares valued at $174,119.16 to be executed on NASDAQ via Fidelity. Acquisition dates show these shares originated from multiple restricted stock vesting events between 2017 and 2019, indicating the shares are from compensation awards rather than recent open-market purchases. The filer previously sold 1,573 and 1,500 shares in August and September 2025, generating gross proceeds of $41,826.23 and $45,243.50 respectively. From a market-impact perspective, the disclosed quantities are small relative to the total outstanding shares reported at 19,018,573, implying limited dilution or liquidity impact.

Corporate Governance Expert

TL;DR Disclosure is routine Rule 144 notice tied to vested compensation; no new governance issues disclosed.

The document supplies required Rule 144 details: broker identity, lot-by-lot acquisition via restricted stock vesting, nature of payment as compensation, and recent sales history. The representation about lacking undisclosed material adverse information is standard. There is no indication in the filing of insider trading plan dates, instructions under Rule 10b5-1, or any disclaimers beyond the statutory attestation. Governance implications are procedural; the filing does not reveal departures, policy changes, or material corporate events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5166	174119.16	19018573	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/15/2018	Restricted Stock Vesting	Issuer			190	02/15/2018	Compensation
Common	08/15/2018	Restricted Stock Vesting	Issuer			1346	08/15/2018	Compensation
Common	11/15/2017	Restricted Stock Vesting	Issuer			1073	11/15/2017	Compensation
Common	02/15/2019	Restricted Stock Vesting	Issuer			1072	02/15/2019	Compensation
Common	11/15/2018	Restricted Stock Vesting	Issuer			1011	11/15/2018	Compensation
Common	05/15/2019	Restricted Stock Vesting	Issuer			474	05/15/2019	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	08/19/2025	1573	41826.23
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	09/02/2025	1500	45243.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is the size and value of the proposed sale in the NKTR Form 144?

The filing reports a proposed sale of 5,166 common shares with an aggregate market value of $174,119.16.

When is the NKTR proposed sale scheduled and on which exchange?

The approximate date of sale is 09/04/2025 and the transaction is to occur on NASDAQ through Fidelity Brokerage Services.

How were the shares being sold acquired according to the filing?

All disclosed lots were acquired via restricted stock vesting between 11/15/2017 and 05/15/2019 as compensation.

Has the filer sold shares recently prior to this notice?

Yes; the filing lists sales of 1,573 shares on 08/19/2025 for $41,826.23 and 1,500 shares on 09/02/2025 for $45,243.50.

Does the filing state any undisclosed material information about Nektar Therapeutics?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.